Introduction
Over the last two decades, the antiphospholipid antibody syndrome (APS) has emerged as a subject of intense clinical and scientific interest. This syndrome is characterized by the presence of autoantibodies that bind to negatively charged phospholipids or the phospholipid complexes. Patients with significant levels of antiphospholipid antibodies are prone to fetal loss, autoimmune thrombocytopenia and thrombotic events. [1] [2] [3] Nevertheless, the wide spectrum of clinical associations of APS includes almost every organ and system in the human body. The examples include findings of epilepsy, chorea, thrombocytopenia, erythema nodosum and livedo reticularis in APS patients. 4, 5 There is no doubt now that aPLs induce a procoagulant state, and thus contribute to the thrombotic manifestations of APS. However, the recent data show that aPLs may also be associated with atherosclerosis, in addition to their relation to thrombosis. 6 In the last decade, atherosclerosis has been identified as a significant feature of patients with systemic lupus erythematosus (SLE) and those with APS. Although data regarding the objective assessment of atheroma progression in these patients is scarce, an increased risk of atherosclerosis-related events has been reported in different studies. 7, 8 Cardiovascular disease, on the other hand, remains one of the main contributors to morbidity and mortality in the developed world. One of the known risk factors of cardiovascular disease are hypercholesterolemia and atherosclerosis. 9 The contribution of these asymptomatic states for cardiovascular morbidity is worth evaluating in groups of patients with potential risk such as SLE or/and APS.
The assessment of arterial stiffness is an attractive method for evaluation of cardiovascular status for number of reasons. Arterial stiffness is correlated with severity of coronary artery disease 10 and severity of carotid artery disease, 11 and predicts future morbidity and mortality. 12, 13 Pulse wave analysis is well tolerated, cost effective and a validated measure of vascular status in high-risk groups of patients (coronary artery disease, hypertension, diabetes mellitus (DM) and renal failure). 14 In the present study, we used pulse wave analysis to assess vascular compliance in APS patients. The vascular bed status in these patients was compared with that in healthy subjects and patients suffering from DM.
Patients and methods

Patients
Patients with APS or aPLs positivity who were attending the rheumatology outpatient clinic at Barzilai Medical Center, Ashkelon, Israel were eligible for the study. The diagnosis of primary APS was made according to Supporo criteria. 15 All the patients were divided into two groups according to warfarin treatment status. In the first group (APS-1), 14 patients with primary and secondary APS, major vascular thrombotic event and warfarin treatment were enrolled. The second group (APS-2) consisted of 11 patients with anticardiolipin antibodies (aCL) or lupus anticoagulant (LAC) positive and symptoms attributable to APS -that is, haemolytic anaemia, kidney disorder (proteinuria) who need no warfarin treatment, or those with APS, who refused the warfarin and fractionated heparin treatment.
Exclusion criteria were DM (fasting blood glucose 4126 mg/dl), renal function impairment (creatinine blood level 41.4 mg/dl), cardiac arrhythmia at the time of the study or valvular heart disease.
Control subjects
The 61 control subjects consisted of 33 healthy people (HP) who were hospital workers and 28 patients with non-insulin-dependent DM. All subjects of control groups were randomly selected from among people who underwent pulse wave analysis in our clinic for arterial hypertension. The control subjects and APS-2 patients were matched for age, but there was a difference in age between APS-1 patients and all other groups. All patients and control subjects were matched according to their gender.
The study was approved by the Ethics Committee of the Hospital. All patients and control subjects signed inform consent forms.
All study subjects completed a questionnaire to assess their smoking status, coronary vascular events in the past and current medication use.
Biochemical assays
Blood samples were taken at the fasting state. A complete blood cell count, renal and liver functions, lipid profile and glucose level were determined. Patients with APS and warfarin treatment were tested for prothrombin time/international normalized ratio (PT/INR) on the day of pulse wave analysis.
Identification of aCL is carried out by enzymelinked immunosorbent assay (commercial ELISA kit, BL Diagnostika, Mainz, Germany). The Results are expressed in standardized aCL IgG (GPL) and aCL IgM (MPL) units: each unit has the binding activity of 1 eg/ml of purified aCL. Lupus anticoagulant activity was detected by dilute Russell's Viper Venom Test, and beta-2 GP-1 Ab by enzymelinked immunosorbent assay (BL Diagnostika, Germany).
Pulse wave analysis
Pulse wave analysis using an HDI/PulseWave CR-2000 analyzer (Hypertension Diagnostics, Eagan, MN, USA) was performed. The studied subjects were lying supine on the table, with a blood pressure cuff placed on the left arm and a pressure transducer placed on the right radial artery. The age, height and weight of each subject were entered into the instrumentation control panel before the automated measurement of heart rate, systolic and diastolic blood pressure, and assessment of the pulse wave at the right radial artery. After data acquisition, the inbuilt software analysed the waveform, based on a modified Windkessel model of the circulation, to calculate arterial elasticity and systemic vascular resistance (SVR). Data calculated included the body mass index (BMI), pulse pressure, small artery elasticity (SAE), large artery elasticity (LAE) and SVR.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences, 11.0 (SPSS, Chicago, IL, USA). Differences in levels of numeric variables between matched cases and controls were tested by independent samples t-test, as appropriate. Differences between numeric variables of unmatched parameters were tested by analysis of variance (ANOVA) test. Associations of SAE, LAE and SVR with age, and SAE with the level of hypocoagulation (INR) were examined using a linear regression model. The data were presented as mean7standard deviation (s.d.). P-values less than 0.05 were considered significant.
In order to eliminate the affect of age factor on studied variables, we used the method of analysis of covariance (ANCOVA). This method allows compensating for biases among studied samples.
Results
Clinical characteristics
The patient group consisted of 25 subjects with APS or aPLs positivity. Six of the above patients suffered from SLE (three SLE patients in each group). Eleven patients in APS-1 group were diagnosed as primary APS according to Supporo criteria, 14 and three patients suffered from SLE and secondary APS. Five Arterial compliance T Reitblat et al of these patients were after venous thrombotic event. Deep vein thrombosis (DVT), and nine suffered from arterial thrombotic event, cerebrovascular accident (CVA) or transient ischemic attack (TIA). In APS-2 group, three patients were after a venous thrombotic event, two after TIA, two with pregnancy loss, two with livedo reticularis on the skin, one with a kidney disorder and one with haemolytic anaemia.
The APS-1 group consisted of three male and 11 female patients; in the APS-2, there were two male and nine female patients.
All patients of the APS-1 group were treated by warfarin as recommended.
The HP group consisted of six male and 27 female patients and in the DM group there were six male and 22 female patients.
Mean age in APS-1 was 43.376.8 years, which differed significantly from other groups (Po0.05). Mean age in APS-2, DM and HP subjects was 53.2711.2, 54.8711.6, 50.378.4 years, respectively. There was no significant difference in age between these groups.
There were more smokers in the health control group -75.5%, and current smoker status did not differ significantly between the APS groups and the DM patients. Patients who suffered from arterial hypertension were well controlled and their blood pressure did not differ significantly between the APS patients and the DM patients, although treatment for hypertension was more common in DM group.
Antihypertensive agents used in APS-1 and APS-2 groups were angiotensin-converting enzyme (ACE) inhibitors. Patients with hypertension in DM group were treated by a combination of calcium channel blockers, b-blockers, ACE inhibitors and diuretics; those without hypertension in DM group received ACE inhibitors.
Patients and controls did not differ by BMI or lipid profiles.
Demographic and clinical data for patients and controls are shown in Table 1 .
Antiphospholipid antibodies and coagulation status All APS patients with warfarin treatment were with a stable INR level for at least 2 months, and underwent INR evaluation on the day of pulse wave analysis. The mean INR value was 2.81 (range 2.5-3.0).
The mean aCL IgG value for the APS-1 group was 31.19 Gpl/ml (range 12-56 Gpl/ml, normal up to 10 Gpl/ml) and IgM antibody was 6.83 Mpl/ml (range 2.8-13.0 Mpl/ml, normal up to 7 Mpl/ml). In the APS-2 group, the values of aCL were 28.55 Gpl/ ml (range 2.8-56.1 Gpl/ml) and 9.94 Mpl/ml (range 3.3-17.0 Mpl/ml), respectively. The mean level of There was no significant difference in the level of aPLs between the groups. In the APS-1 group, five patients were LAC-positive, and in the APS-2 group LAC was positive in four patients.
Vascular status
After adjustment for age, we found that the mean values of SAE in the APS-1 group differed significantly from that of the APS-2 group -6.471.8 ml/ mm Hg Â 100 vs 3.4171.2 ml/mm Hg Â 100, Po0.001. The normal mean value for SAE in our laboratory for age 40-60 years is 6.0 ml/mm Hg Â 100. The APS-1 group patients did not differ in SAE from the HP group, which was 5.5473.4 ml/mm Hg Â 100 (P40.05). The mean values of SAE in groups APS-2 and DM were significantly lower than in two previous groups and were almost equal -3.4171.2 ml/mm Hg Â 100 and 4.272.37 ml/mm Hg Â 100 (P40.05), respectively (Table 2) . Regression analysis showed inverse correlation between age and SAE in APS-2, DM and health groups (Po0.05). The slope of this relationship was the greatest for the APS-2 group. In the APS-1 group, the slope of age -SAE association had only a slight angle, showing a very weak association (P ¼ 0.99), as if SAE in these patients did not correlate with age ( Figure 1) .
The regression analysis showed a strong association between SAE and INR (Figure 2 ) in the APS-1 group (P ¼ 0.012).
The mean levels of LAE did not vary significantly between all the groups. However, DM patients showed a tendency to lower LAE -12.174.6 ml/ mm Hg Â 10 in comparison to three other groups (16.779.5 ml/mm Hg Â 10 for APS-1, 16.076.36 ml/ mm Hg Â 10 for HP and 14.275.6 ml/mm Hg Â 10 for APS-2).
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Discussion
Although antiphospholipid antibodies have not yet been established as independent risk factors for atherosclerosis, a number of works have suggested this association. It has already been shown that high level of aCL IgG was an independent risk factor for such atherosclerotic events as myocardial infarction or cardiac death in middle-aged men. 16, 17 The high level of aCL was also found in patients with atherosclerotic peripheral vascular disease in comparison to a health group. 18 The fact that aCL may be associated with an atherosclerotic process was shown in animal models, 19 and in laboratory studies. [20] [21] [22] Pulse wave analysis provides measurements that capture both capacitive (storage) and cushioning (oscillatory) arterial functions. It uses the arterial pulse contour to provide an assessment of the large artery (capacitance) behaviour and the behaviour of smaller arteries that represent the primary source of reflected waves or oscillations in the arterial system. We have mentioned already that the pulse wave analysis is an attractive method to study the early atherosclerotic changes in the vascular wall. A recently developed, noninvasive instrument based on pulse contour analysis is able to estimate both large and small arterial compliance by using a piezoelectric transducer over the radial artery. A computer algorithm calculates large artery compliance (C1), that is capacitive compliance, and small artery compliance -C2 (oscillatory compliance). C2 is particularly sensitive to the changes in the vessel wall associated with hypertension, DM, 23 congestive heart failure, 24 smoking status 25 and age. 26 These studies showed decrease in SAE in patients suffering from arterial hypertension, DM and congestive heart failure. It has already been shown that SAE tends to decrease with age, and this regression is linear.
The modern antihypertensive drugs may affect vascular compliance. Although the data are contradictory, it seems that the compliance increases by vasodilators, but less so or not at all by b-blockers or thiazide. 24 In our DM and HP groups, we found the similar changes as in other studies -that is, SAE was the lowest in the DM group, and regression in SAE with age was also shown. The patients of APS-2 group showed the values of SAE comparative with patients with DM, that is reduced SAE.
In the APS-1 group, we have found very interesting data: SAE was not reduced, as in the APS-2 group, and it was similar to that in the HP group. Moreover, we have not found an association between SAE and age as in all other groups. This group differed from the other groups by warfarin treatment. Assuming this fact, the regression analysis of this association was performed. We have shown therefore that there is a strong association between INR and SAE. We do not yet have an explanation for this, and we did not find relationship between warfarin treatment and its influence on endothelial function or small vessel elasticity in recent literature. We can only suggest that warfarin changes blood rheology, thus affecting the results of pulse wave analysis.
There was no significant difference in LAE and SVR between studied groups, although DM patients showed the tendency to poorer compliance of large arteries and higher SVR that is compatible with results of other studies. 21 In the APS-2 group, values of LAE and SVR are close to these in the DM group, thus suggesting the reduced compliance in APS-2 patients. In APS-1 and HP, the values of LAE and SVR were almost similar and within normal range.
It seems that there was not a significant influence of antihypertensive treatment on vascular compliance in our patients. The most treated group, patients with DM, showed the lowest SAE.
In conclusion, this pilot study has showed reduced arterial elasticity in APS patients without warfarin treatment. These data support the hypothesis that APS is associated with diffuse changes in the arterial wall and may be a risk factor for atherosclerotic disease. Patients treated with warfarin did not show reduced compliance of the arterial wall. The question is whether warfarin improves artery wall elasticity. We could not answer the question in this particular study. Therefore, further prospective clinical and laboratory studies are required. Furthermore, we plan to investigate vascular compliance in all patients before warfarin treatment and during the treatment.
The early detection of vascular damage may improve the health status of APS patients. Pulse wave analysis may be a helpful tool for such investigation and for treatment decisions.
What is known about this topic K In the last decade atherosclerosis has been identified as a significant feature of patients with systemic lupus erythematosus and those with antiphospholipid antibody syndrome 7 K High level of IgG anticardiolipin antibodies is an independent risk factor for such atherosclerotic event such as myocardial infarction
